Abraxis BioScience Launches Ondansetron Injection, USP

Business Wire, Jan 4, 2007

LOS ANGELES -- Abraxis BioScience, Inc. (NASDAQ: ABBI), an integrated, global biopharmaceutical company, today announced that it has launched Ondansetron Injection, USP, the generic equivalent of GlaxoSmithKline's Zofran([R]) Injection. According to IMS, sales in 2005 of ondansetron in the United States exceeded $587 million. The company markets ondansetron in AP-rated single-dose and multiple-dose bar coded, latex-free vials.

Ondansetron Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin, and prevention of postoperative nausea and/or vomiting.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab[TM] platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE([R]), was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the NASDAQ Stock Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.